U.S., Nov. 1 -- ClinicalTrials.gov registry received information related to the study (NCT07223502) titled 'A Study Comparing the Clinical Benefit of Finerenone Versus a Fixed Dose Combination (FDC) of Extended-Release Torsemide and Spironolactone in Patients With Hypertension and Chronic Kidney Disease' on Oct. 29.
Brief Summary: A study Comparing the Clinical Benefit of Finerenone Versus a Fixed-Dose Combination (FDC) of Extended-Release Torsemide and Spironolactone in Patients with Hypertension and Chronic Kidney Disease.
Study Start Date: Dec. 01
Study Type: INTERVENTIONAL
Condition:
Hypertension (HTN)
Intervention:
DRUG: Combination Product: FDC of spironolactone and ER torsemide
The usual starting torsemide daily dose ranges f...